Cryo-Cell International, Inc.
CCEL
$4.20
-$0.10-2.33%
AMEX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.29% | 1.10% | 2.33% | 2.05% | 1.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.29% | 1.10% | 2.33% | 2.05% | 1.94% |
| Cost of Revenue | -39.23% | -36.68% | -35.91% | -35.24% | 40.82% |
| Gross Profit | 23.20% | 24.20% | 26.43% | 25.58% | -12.61% |
| SG&A Expenses | 4.04% | 7.76% | 6.28% | 8.46% | 10.01% |
| Depreciation & Amortization | 34.31% | 17.90% | -26.73% | -56.98% | -49.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.26% | -11.66% | -13.11% | -10.74% | 19.14% |
| Operating Income | 3,118.63% | 1,629.10% | 525.97% | 1,633.90% | -103.27% |
| Income Before Tax | 111.76% | 113.01% | 118.45% | 120.98% | -479.78% |
| Income Tax Expenses | 156.31% | 154.08% | 159.59% | 162.51% | -559.14% |
| Earnings from Continuing Operations | 94.70% | 98.16% | 101.32% | 104.22% | -456.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.70% | 98.16% | 101.32% | 104.22% | -456.17% |
| EBIT | 3,118.63% | 1,629.10% | 525.97% | 1,633.90% | -103.27% |
| EBITDA | 734.04% | 671.15% | 2,742.54% | 288.75% | -89.05% |
| EPS Basic | 94.51% | 98.09% | 101.31% | 104.14% | -460.18% |
| Normalized Basic EPS | 341.35% | 338.49% | 212.39% | 249.71% | -130.70% |
| EPS Diluted | 93.40% | 97.26% | 100.78% | 104.02% | -463.89% |
| Normalized Diluted EPS | 329.66% | 323.69% | 209.62% | 246.18% | -132.11% |
| Average Basic Shares Outstanding | -1.40% | -2.06% | -2.56% | -2.52% | -2.53% |
| Average Diluted Shares Outstanding | -1.67% | -1.87% | -1.84% | -1.91% | -1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |